The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Charles T Quinn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Benzaldehydes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Voxelotor (OXBRYTA) was abruptly withdrawn from the global market in September 2024. Clinicians and patients were not prepared for this, and the sudden discontinuation has caused much consternation, uncertainty, and loss of trust.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
- Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID-Profile: Charles T Quinn, Russell E Ware
Zitieren
APA
Quinn, C. T., & Ware, R. E. (2025). The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31475
Vancouver
Quinn CT, Ware RE. The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31475
BibTeX
@article{Quinn2025,
author = {Quinn, Charles T and Ware, Russell E},
title = {The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31475}
}
EUVIMED